Skip to content

No results found

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

BIO Bio-Rad Laboratories, Inc.Class A
$261.28 -0.59% -1.56
Notify me if price changes either direction
Interactive Brokers Logotype

Buy BIO stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 7.1B
Enterprise value 6.9B
Trailing PE 9.4328785
Forward PE 23.226974
PEG Ratio -0.046153598018561
Enterprise to EBITDA 16.073
Enterprise to revenue 2.685
Price to book MRQ 0.9516291
Price to sales TTM 2.7458484

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2025-12-31
Revenue (TTM) 2.6B
EBITDA 480.7M
Diluted EPS TTM 27.86
Total Cash (MRQ) 1.5B
Current ratio (MRQ) 5.621
Operating Cash Flow (TTM) 532.2M

BIO trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent BIO News

Home

No results found

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.